Liberum Capital reissued their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report report published on Tuesday. The firm currently has a GBX 1,900 ($24.80) price target on the stock.

A number of other equities research analysts have also recently commented on GSK. Shore Capital reissued a buy rating on shares of GlaxoSmithKline plc in a report on Wednesday, June 1st. Beaufort Securities reissued a buy rating on shares of GlaxoSmithKline plc in a report on Friday, June 3rd. Morgan Stanley set a GBX 1,500 ($19.58) price target on GlaxoSmithKline plc and gave the company a neutral rating in a report on Tuesday, May 31st. BNP Paribas reissued a neutral rating and set a GBX 1,560 ($20.36) price target on shares of GlaxoSmithKline plc in a report on Thursday, August 4th. Finally, Citigroup Inc. reissued a buy rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of GBX 1,676.44 ($21.88).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1649.50 on Tuesday. GlaxoSmithKline plc has a one year low of GBX 1,227.50 and a one year high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,652.88 and its 200 day moving average price is GBX 1,532.04. The stock’s market capitalization is GBX 80.18 billion.

The firm also recently declared a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.12%. The ex-dividend date is Thursday, August 11th.

In other GlaxoSmithKline plc news, insider Cartwright,Stacey purchased 461 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 1st. The shares were acquired at an average cost of GBX 1,559 ($20.35) per share, with a total value of £7,186.99 ($9,381.27). Also, insider Witty,Sir Andrew P sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.